CN103505535B - Medicine used for treating psoriasis as well as extraction method, extract and application thereof - Google Patents
Medicine used for treating psoriasis as well as extraction method, extract and application thereof Download PDFInfo
- Publication number
- CN103505535B CN103505535B CN201210225558.0A CN201210225558A CN103505535B CN 103505535 B CN103505535 B CN 103505535B CN 201210225558 A CN201210225558 A CN 201210225558A CN 103505535 B CN103505535 B CN 103505535B
- Authority
- CN
- China
- Prior art keywords
- medicine
- extract
- parts
- obtains
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicine used for treating psoriasis as well as an extraction method, extract and an application thereof. The medicine used for treating psoriasis is prepared from the following raw materials in parts by weight: 6-10 parts of bulgaria inquinans, 6-12 parts of Chinese angelica, 6-15 parts of cortex dictamni and 3-9 parts of liquorice. The medicine used for treating psoriasis has the effects of relieving itching, calming, activating blood, dissipating stasis, reducing blood viscosity, improving microcirculation, clearing heat, drying dampness, detoxifying and resisting to bacteria, has a certain photodynamic effect and can enhance the treatment effect, so that the medicine used for treating psoriasis has an especially obvious psoriasis treatment effect.
Description
Technical field
The invention belongs to Chinese medicine composition field, treat psoriatic medicine and preparation method thereof in particular to one.
Background technology
Psoriasis (Psoriasis), also known as psoriasis, be a kind of common chronic dermatosis, it is characterized in that the pimple, the erythema that occur differing in size, surface coverage silvery white squama, clear border, is apt to occur in scalp, extremity stretch side and back.Male is more than women.Winter in spring easily recurs or increases the weight of, and many alleviations summer and autumn.
Onset of psoriasis reason more complicated, the cause of disease is not yet clear and definite.Most scholar thinks in recent years, with heredity, infect, dysbolismus, immune dysfunction, endocrine disturbance be relevant.Become more and more general now, the city particularly developed.Psoriasis is not a kind of infectious disease, but because the skin problem of psoriatic, often brings great body and mind misery and financial burden to patient.
Western medical treatment psoriasis mainly eliminates symptom, avoids further deterioration, cannot effect a radical cure.Side effect is larger.Because psoriatic pathological change is epidermal cell proliferation, so all focused on the cancer therapy drug using energy antiproliferative effect in the past, the fifties reinstated aminopterin, used methotrexate (METHOTREXOTE) after a while, the seventies reinstates ethyliminum, bimolane etc., but these drug side effectes are large, and easily recur after drug withdrawal, then when sending out, the state of an illness is often heavier, treat also more obstinate, as aminopterin easily causes leukopenia, even granulocyte lacks, and also can cause liver cirrhosis and hepatocarcinoma.The toxicity of methotrexate to liver is larger; Because using ethyliminum and bimolane, in recent years district in all parts of the country oneself have tens of example to cause leukemic report.And the traditional Chinese medical science traditional remedies treatment psoriasis due to therapeutic effect not energetic, neither be very desirable.
Describe a kind of Bulgaria inquinans in Chinese patent application CN 03128560.0 and CN 01118726.3 or its mycelial extract is used for the treatment of psoriasis, this medicine has certain curative effect, does not produce at present and goes on the market, and needs further to study.
Scientific and technical literature " Jing Haixia; Sheng Wanxiang; Duan Dejian etc.; in the impact [J] of Radix Angelicae Sinensis polysaccharide on Expression Levels of PCNA in Psoriasis-like Lesions of Guinea Pigs. Chinese skin cypridology magazine; 01 phase in 2008 " in, report the impact of Radix Angelicae Sinensis polysaccharide on cell proliferative nuclear antigen (PCNA) expression in Cavia porcellus ear Pigs with Psoriasis, research conclusion is that Radix Angelicae Sinensis polysaccharide has therapeutical effect to the hard of hearing Psoriasis-like Model of Cavia porcellus that Propranolol brings out, may be relevant with PCNA expression in its reduction skin lesion.
Summary of the invention
For solving above-mentioned problems of the prior art, the invention provides one and treating psoriatic medicine and preparation method thereof.
Specifically, the invention provides:
(1) one is used for the treatment of psoriatic medicine, and wherein, this medicine is made up of the crude drug of following weight portion: Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part.
(2) medicine Gen Ju (1), wherein, the weight portion of described crude drug is respectively: Bulgaria inquinans 10 parts, Radix Angelicae Sinensis 10 parts, Cortex Dictamni 10 parts, 6 parts, Radix Glycyrrhizae.
(3) one is used for the treatment of psoriatic medicine, and wherein, this medicine is made up of the crude drug of following weight portion: Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part, Radix Salviae Miltiorrhizae 9-15 part.
(4) medicine Gen Ju (3), wherein, the weight portion of described crude drug is respectively: Bulgaria inquinans 10 parts, Radix Angelicae Sinensis 10 parts, Cortex Dictamni 10 parts, 6 parts, Radix Glycyrrhizae, Radix Salviae Miltiorrhizae 10 parts.
(5) a kind of extracting method according to the medicine in (1)-(4) described in any one, it comprises:
By described crude drug coarse pulverization, successively with alcohol reflux 2-4 time of 3-7 times of weight, each extraction time is 1-3 hour, filters, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtains extract.
(6) extracting method Gen Ju (5), it comprises: by described crude drug coarse pulverization, uses the alcohol reflux 3 times of 5 times of weight successively, time is respectively 2 hours, 1.5 hours, 1.5 hours, filters, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtain described extract.
(7) a kind of extract obtained according to (5) or the extracting method described in (6).
(8) extract Gen Ju (7) for the preparation for the treatment of psoriatic medicament in purposes.
(9) a kind of preparation method of the capsule according to the medicine in (1)-(4) described in any one, it comprises:
A) by described crude drug coarse pulverization, successively with the alcohol reflux 3 times of 3-7 times of weight, each extraction time is 1-3 hour, filters, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtains extract;
B) get the extract that step a) obtains to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, pours into capsule, obtains capsule.
(10) capsule that obtains of a kind of preparation method Gen Ju (9).
Medicine of the present invention compared with prior art has the following advantages and good effect:
Medicine of the present invention has antipruritic, calm, blood circulation promoting and blood stasis dispelling, reduction blood viscosity, improves microcirculation, heat clearing and damp drying, removing toxic substances, antibacterial effect, it has certain photodynamics can increase therapeutic effect, and medicine of the present invention has the psoriatic effect of significant treatment especially.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The present inventor be have been surprisingly found that by a large amount of research, and the combination medicine form of Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae can provide the psoriatic effect for the treatment of useful especially, and its effect is better than any one-component.
The drug action mechanism of Combined effects of the present invention is:
Bulgaria inquinans is the dry sporophore of Bulgaria inquinans section fungus Bulgaria inquinans Bulgaria inquinans (Pers.) Fr., summer and autumn gather, dry, Forest in Changbai Mountain Forest Region, the place of production, after common local resident's continuous several times or once excessive edible glue gyro, through exposure in sunshine, the body exposure positions such as face occur red and swollen, especially attach most importance to lip.Therefore locality is " snoot mushroom " or " arch mouth mushroom " also known as Bulgaria inquinans.
The main chemical compositions of Bulgaria inquinans is ergosterol, oxalic acid, galactitol and benzofluoranthrene quinones etc.Bulgaria inquinans has effect of heat-clearing and toxic substances removing, promoting blood circulation to remove obstruction in the collateral, the psoriatic pharmacological action of Bulgaria inquinans extract for treating is very special, be different from traditional Chinese medicine, photodynamic effect (photosensitivity reaction) is there is after patient takes, affected part can be rubescent and have the reaction of similar inflammation after sunlight irradiates, within after drug withdrawal 1-2 days, disappear, this process has benefit very to psoriatic recovery from illness.This photodynamic effect is similar to the photochemotherapy (PUVA) in western medicine, and does not have the common toxic and side effects of photochemotherapy.
Radix Angelicae Sinensis has the effect of enriching blood and invigorating blood circulation, and its chemical composition is volatile oil composition and polysaccharide composition mainly, such as butylidenephthalide (Butylidene phthalide), nopinene (β-Pinene), australene, camphene (Camphene), to P-cymene (p-Cymene), β-phellandrene (β-Phellandrene), myrcene (Myrcene), alloocimene (Allo-ocimene), 6-normal-butyl-cycloheptadiene-Isosorbide-5-Nitrae (6-n-butyl-cycloheptadiene-1,4), 2-methyl-dodecanoic-5-ketone (2-Methyl-dodecane-5-one), 1-Phenylethanone. (Acetophenone), β-bisabolence (β-Bisabolene), different Rhizoma Acori Graminei alkene (Isoacroraene), acoradiene (Acoradiene), cuparene (Chamigrene), α-himachalene (α-Cedrene), ligustilide (Ligustilide), normal-butyl Si Qingization Fu lactone (n-Butyl-tetrahydrophthalide), Zheng butylphthalide (n-Butyl-phthalide), Zheng Ding Xi Fu lactone (n-Buty-lidene phthalide), n-dodecane alcohol (Dodecanol), bergapton (Bergapten) etc.There is blood vessel dilating, promote humoral immunization, antibacterial effect.
Cortex Dictamni has heat clearing and damp drying, dispelling wind for relieving itching, the effect of removing toxic substances, its chemical composition is dictamine (dictamnine) mainly, .beta.-fagarine (skimmianine), .gamma.-fagarine (g-fagarine), front .beta.-fagarine (preskimmianine), different speckle boils forest-grass alkali (isomaculosindine), limonin (limonin, dictamnolactone), obacunone (obakunone), fraxinellon (fraxinellone), and sitosterol, acidic materials and Saponin etc. Herb is still containing 7-geranyloxycoumarin (aurapten), Bergapten (bergapten). aerial parts is also containing psoralen (psoralen), xanthotoxin (xanthotoxin) and volatile oil, root bark is still containing campesterol (campesterol).There is antibacterial, antifungal, antipyretic, the effect that increases cardiac muscular tension.
Radix Glycyrrhizae has the effect of heat-clearing and toxic substances removing, its chemical composition mainly glycyrrhizic acid, liquiritin etc., such as: glycyrrhizin, enoxolone, liquiritin, isoliquiritin, neoliquriitin, neoisoliquiritin, glycyrrhizin, isoliquiritigenin and licoricidin (+)-Licoricidin., glycyrol, isoglycyrol, 7-methylcoumarin essence, umbelliferone etc.There is the effect of antibacterial, antiinflammatory, antiallergic action, removing toxic substances, and have the effect of adrenocortical hormone sample.
Pharmaceutical composition of the present invention have followed the theory of traditional Chinese medical science monarch, have followed the theory of instruction of Chinese Medicine theory application in TCM, Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae four Chinese medicine are according to monarch prescription, wherein, Bulgaria inquinans is monarch drug, when being classified as ministerial drug, Cortex Dictamni is adjuvant drug, Radix Glycyrrhizae is for making medicine.
From the angle of modern Chinese medicine chemistry, four Chinese medicine chemical constituent of the present invention is definite, Bulgaria inquinans mainly containing ergosterol, oxalic acid, galactitol and benzofluoranthrene quinones composition, Radix Angelicae Sinensis mainly containing volatile oil composition and polysaccharide composition, Cortex Dictamni mainly containing alkaloids composition, Radix Glycyrrhizae mainly containing glycyrrhizic acid constituents, crude drug effective ingredient after extracting is concentrated, and drug effect is obvious.
Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae therapeutic alliance psoriasis show the effect of significant Synergistic, and curative effect is better than any one-component.Wherein, Bulgaria inquinans can play heat-clearing and toxic substances removing, promoting blood circulation to remove obstruction in the collateral, antipruritic, calm effect as monarch drug, it has certain photodynamics can increase therapeutic effect, Radix Angelicae Sinensis as ministerial drug have enrich blood invigorate blood circulation, blood vessel dilating, antibacterial effect, Cortex Dictamni has the effect of heat clearing and damp drying, dispelling wind for relieving itching, removing toxic substances as adjuvant drug, Radix Glycyrrhizae, as making medicine, has effect that is antibacterial, removing toxic substances.Four work, the effect of heat-clearing and toxic substances removing, promoting blood circulation to remove obstruction in the collateral, antipruritic, calm, antibacterial, removing toxic substances, having can the alleviating and reverses psoriasis pathology and change of highly significant, and has and treats psoriatic effect especially significantly.
In addition, the present invention, on the basis of above-mentioned four medicines, can increase Radix Salviae Miltiorrhizae again.Radix Salviae Miltiorrhizae has the effect of blood circulation promoting and blood stasis dispelling, its chemical composition is mainly: diterpene Quinone Pigments, TANSHINONES (tanshinone) I, II A, II B, cryptotanshinone (cryptotanshinone), iso tanshinone (isotanshinones) I, II, different cryptotanshinone (1socryptotanshinone), miltirone (miltirone), Methyl tanshinoate (methyl tanshinonate), hydroxytanshinone ⅡA Hydroxytanshinone IIA. (hydroxytanshinone), dihydrotanshinone Ⅰ (dihydrotanshinone I), neotanshinone A, second, third, methylene tanshinquinone (methylenetanshinquinone) and carnosol (salviol).Another report closes ferruginal (ferruginol), Δ l-miltirone (Δ l-dehydromiltirone), Δ l-tanshinone IIA (Δ l-dehydrotanshinone IIA), danshenxinkun fourth (danshenxinkun D) and 1,2-dihydro Radix Salviae Miltiorrhizae quinone etc.Have and improve microcirculation, promote the reparation of tissue and regeneration, suppress the effect of the fibroblast of hyperplasia.In the present invention, further, Radix Salviae Miltiorrhizae can be ministerial drug with Radix Angelicae Sinensis altogether, plays and reduces psoriatic's blood viscosity further, improve microcirculatory effect.
Specifically, the invention provides one and treat psoriatic medicine, this medicine by comprise Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae crude drug make, also can comprise pharmaceutically acceptable pharmaceutic adjuvant.
Prepare the crude drug that medicine of the present invention adopts, according to the ratio of the weight of crude drug, comprise Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part.
Prepare the crude drug that medicine of the present invention adopts, according to the ratio of the weight of crude drug, preferably include Bulgaria inquinans 10 parts, Radix Angelicae Sinensis 10 parts, Cortex Dictamni 10 parts, 6 parts, Radix Glycyrrhizae further.
Further preferably, prepare the crude drug that medicine of the present invention adopts, according to the ratio of the weight of crude drug, containing Bulgaria inquinans 6-10 part, Radix Salviae Miltiorrhizae 9-15 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part.More preferably containing Bulgaria inquinans 10 parts, Radix Salviae Miltiorrhizae 10 parts, Radix Angelicae Sinensis 10 parts, Cortex Dictamni 10 parts, 6 parts, Radix Glycyrrhizae.
In order to reach more concentrated pharmacological action and better drug effect, preferably crude drug Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae are made medicine of the present invention through extraction process.
Can be obtained by methods such as the water extraction of routine, ethanol extraction, water extract-alcohol precipitations, preferably be extracted by following method and obtain:
Crude drug coarse pulverization, successively with alcohol reflux 2-4 time of 3-7 times of weight, each extraction time is 1-3 hour, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains getting thing.
Further preferred extracting method is: crude drug coarse pulverization, and use the alcohol reflux 3 times of 5 times of weight successively, the time is 2 hours, 1.5 hours, 1.5 hours, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract.
Medicine preferred oral of the present invention administration, is also applicable to other administering mode, as parenteral, sublingual administration or oral transmucosal administration etc.
The oral delivery form of medicine of the present invention can be any conventional formulations such as tablet, capsule, granule, oral liquid, mixture, effervescent tablet, oral cavity disintegration tablet.Preferably capsule.
The preparation method of the capsule of medicine of the present invention is preferably:
A) crude drug coarse pulverization, use the alcohol reflux 3 times of 3-7 times amount successively, each extraction time is 1-3 hour, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, pours into capsule, obtains capsule.
Mode by the following examples further explains and describes content of the present invention, but these embodiments are not to be construed as limiting the scope of the invention.
Embodiment 1
A) above-mentioned raw materials medicine coarse pulverization, use the alcohol reflux 3 times of 5 times of weight successively, the time is 2 hours, 1.5 hours, 1.5 hours, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, fill capsule.
Embodiment 2
A) above-mentioned raw materials medicine coarse pulverization, use the alcohol reflux 3 times of 5 times of weight successively, the time is 2 hours, 1.5 hours, 1.5 hours, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, fill capsule.
Embodiment 3
A) above-mentioned raw materials medicine coarse pulverization, use the alcohol reflux 3 times of 5 times of weight successively, the time is 2 hours, 1.5 hours, 1.5 hours, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, fill capsule.
Embodiment 4
A) above-mentioned raw materials medicine coarse pulverization, use the alcohol reflux 3 times of 5 times of weight successively, the time is 2 hours, 1.5 hours, 1.5 hours, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, fill capsule.
Embodiment 5
A) above-mentioned raw materials medicine coarse pulverization, use the alcohol reflux 3 times of 5 times of weight successively, the time is 2 hours, 1.5 hours, 1.5 hours, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, fill capsule.
Embodiment 6
A) above-mentioned raw materials medicine coarse pulverization, use the alcohol reflux 3 times of 5 times of weight successively, the time is 2 hours, 1.5 hours, 1.5 hours, and filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, fill capsule.
The beneficial effect of medicine of the present invention is verified further below by way of test example:
Test example 1: medicine of the present invention is on the impact of Animal Models of Psoriasis---medicine of the present invention is on the mitotic impact of mouse oestrogen phase vaginal epithelial cell
Experiment purpose: psoriatic pathological characters is cutaneous lesion epidermis cell hyper-proliferative and parakeratosis.The mouse vagina epithelial cell proliferation being in the estrogen phase enlivens, and is the common model evaluating curing psoriasis medicine.
Experimental agents: medicine group of the present invention is drug extract extract powder of the present invention, is mixed with debita spissitudo before use with distilled water; Blank group is distilled water; Positive control drug group is Etretinate granule (Radix Sophorae Flavescentis, Radix Glycyrrhizae, Cortex Dictamni, Radix Saposhnikoviae, Rhizoma Smilacis Glabrae, Periostracum Cicadae, Cortex Phellodendri, Radix Rehmanniae, Flos Lonicerae, Radix Paeoniae Rubra, Fructus Forsythiae, Radix Angelicae Sinensis); Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Radix Salviae Miltiorrhizae extract group, Cortex Dictamni extract group, Radix Glycyrrhizae extract group, for extracting with reference to the method described in embodiment 1 extract obtained, are mixed with debita spissitudo with distilled water before use.
Experimental technique: Kunming kind female mice 130, only, lumbar injection diethylstilbestrol 0.2mg/ only, every day 1 time, continuous 3 days, makes it be in the estrogen phase, within 4th, is divided into 13 groups at random 20-30g/, often organizes 10.Divide into groups by table 3, every day gastric infusion 1 time, continuous 3 days, 2 hours lumbar injection colchicine 2mg/kg after last administration, put to death mice after 4 hours and get vagina, 10% formalin is fixed, the conventional film-making of paraffin embedding, HE dyes, and count the mitosis number of 300 vagina epithelium basal cells under light microscopic, its percentage rate is mitotic index.
Experimental result is in table 1.
Table 1: medicine of the present invention is on the mitotic impact of mouse oestrogen phase vaginal epithelial cell (n=10)
Experiment conclusion: medicine of the present invention has obvious inhibitory action (P < 0.05, P < 0.01) to mouse oestrogen phase vaginal epithelial cell mitosis.Wherein, the pharmacological action of the middle and high dosage group of medicine of the present invention is obviously better than positive control drug Etretinate granule.Further, the pharmacological action of medicine group of the present invention is obviously better than single Radix Salviae Miltiorrhizae extract group, Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Cortex Dictamni extract group and Radix Glycyrrhizae extract group, thus medicine of the present invention has synergy.
Test example 2: the impact that the impact-of the present invention medicine of medicine of the present invention on Animal Models of Psoriasis generates mouse tail epidermal granular cell
Experiment purpose: psoriatic pathological characters is cutaneous lesion epidermis cell hyper-proliferative and parakeratosis.The keratinization of mouse tail epidermis is formed similar to mankind psoriatic, lacks granular cell, is the common model evaluating curing psoriasis medicine.
Experimental agents: medicine group of the present invention is drug extract extract powder of the present invention, is mixed with debita spissitudo before use with distilled water; Blank group is distilled water; Positive control drug group is Etretinate granule (Radix Sophorae Flavescentis, Radix Glycyrrhizae, Cortex Dictamni, Radix Saposhnikoviae, Rhizoma Smilacis Glabrae, Periostracum Cicadae, Cortex Phellodendri, Radix Rehmanniae, Flos Lonicerae, Radix Paeoniae Rubra, Fructus Forsythiae, Radix Angelicae Sinensis); Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Radix Salviae Miltiorrhizae extract group, Cortex Dictamni extract group, Radix Glycyrrhizae extract group, for extracting with reference to the method described in embodiment 1 extract obtained, are mixed with debita spissitudo with distilled water before use.
Experimental technique: Kunming mouse 130,20-30g/ only, is divided into 13 groups at random by table 4, often organizes 10, male and female half and half, every day gastric infusion 1 time, successive administration 20 days.Within after last administration 2 hours, put to death whole mice, get apart from Mus root of the tail portion 1.8cm place dorsal skin one rectangular, 10% formalin is fixed, and the conventional film-making of paraffin embedding, HE dyes, and counts the middle eyepiece micrometer scope of 10, scale 132 μm of endoparticle cell number under light microscopic.
Experimental result is in table 2.
Table 2: the impact that medicine of the present invention generates mouse tail epidermal granular cell
Experiment conclusion: the generation of medicine of the present invention to mouse tail granular cell has obvious facilitation (P < 0.05, P < 0.01), and granular cell showed increased, Keratoderma layer obviously thickens.Wherein, the pharmacological action of the middle and high dosage group of medicine of the present invention is obviously better than positive control drug Etretinate granule.Further, the pharmacological action of medicine group of the present invention is obviously better than single Radix Salviae Miltiorrhizae extract group, Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Cortex Dictamni extract group and Radix Glycyrrhizae extract group, thus medicine of the present invention has synergy.
Claims (8)
1. be used for the treatment of a psoriatic medicine, wherein, this medicine is made up of the crude drug of following weight portion: Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part, Radix Salviae Miltiorrhizae 9-15 part.
2. medicine according to claim 1, wherein, the weight portion of described crude drug is respectively: Bulgaria inquinans 10 parts, Radix Angelicae Sinensis 10 parts, Cortex Dictamni 10 parts, 6 parts, Radix Glycyrrhizae, Radix Salviae Miltiorrhizae 10 parts.
3., according to an extracting method for the medicine in claim 1-2 described in any one, it comprises:
By described crude drug coarse pulverization, successively with alcohol reflux 2-4 time of 3-7 times of weight, each extraction time is 1-3 hour, filters, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtains extract.
4. extracting method according to claim 3, it comprises: by described crude drug coarse pulverization, use the alcohol reflux 3 times of 5 times of weight successively, time is respectively 2 hours, 1.5 hours, 1.5 hours, filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtain described extract.
5. the extract that obtains of the extracting method according to claim 3 or 4.
6. extract according to claim 5 for the preparation for the treatment of psoriatic medicament in purposes.
7., according to a preparation method for the capsule of the medicine in claim 1-2 described in any one, it comprises:
A) by described crude drug coarse pulverization, successively with the alcohol reflux 3 times of 3-7 times of weight, each extraction time is 1-3 hour, filters, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtains extract;
B) get the extract that step a) obtains to mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, dry, pulverize under 60 DEG C of-70 DEG C of conditions is 80 order fine powders, pours into capsule, obtains capsule.
8. the capsule that obtains of a preparation method according to claim 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210225558.0A CN103505535B (en) | 2012-06-29 | 2012-06-29 | Medicine used for treating psoriasis as well as extraction method, extract and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210225558.0A CN103505535B (en) | 2012-06-29 | 2012-06-29 | Medicine used for treating psoriasis as well as extraction method, extract and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103505535A CN103505535A (en) | 2014-01-15 |
| CN103505535B true CN103505535B (en) | 2015-05-06 |
Family
ID=49889308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210225558.0A Expired - Fee Related CN103505535B (en) | 2012-06-29 | 2012-06-29 | Medicine used for treating psoriasis as well as extraction method, extract and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103505535B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578461B (en) * | 2018-01-22 | 2021-06-18 | 河南大学 | Cercis chinensis extract, its extraction method and application in preparing antithrombotic medicines |
| CN115531407B (en) * | 2022-10-27 | 2023-04-18 | 黑龙江中医药大学 | Pharmaceutical composition for treating psoriasis, preparation and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390602A (en) * | 2001-06-08 | 2003-01-15 | 中国高科集团股份有限公司北京分公司 | Extract of Jiaotuo conch or its mycelium and preparing process and applicatino of its medicine |
| CN1506110A (en) * | 2000-08-04 | 2004-06-23 | 中国高科集团股份有限公司 | Application of Bulgaria inquinans or its mycelium in preparing medicine |
| CN1714840A (en) * | 2004-06-28 | 2006-01-04 | 广西玉林制药有限责任公司 | Chinese medicine composition for stopping itching and its preparing method |
| CN101757104A (en) * | 2009-12-22 | 2010-06-30 | 北大方正集团有限公司 | Medicament for treating psoriasis |
-
2012
- 2012-06-29 CN CN201210225558.0A patent/CN103505535B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506110A (en) * | 2000-08-04 | 2004-06-23 | 中国高科集团股份有限公司 | Application of Bulgaria inquinans or its mycelium in preparing medicine |
| CN1390602A (en) * | 2001-06-08 | 2003-01-15 | 中国高科集团股份有限公司北京分公司 | Extract of Jiaotuo conch or its mycelium and preparing process and applicatino of its medicine |
| CN1714840A (en) * | 2004-06-28 | 2006-01-04 | 广西玉林制药有限责任公司 | Chinese medicine composition for stopping itching and its preparing method |
| CN101757104A (en) * | 2009-12-22 | 2010-06-30 | 北大方正集团有限公司 | Medicament for treating psoriasis |
Non-Patent Citations (1)
| Title |
|---|
| 中医药治疗银屑病20例体会;黄锦兆;<<实用中西医结合临床>>;20090731;第9卷(第4期);74-75 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103505535A (en) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1315525C (en) | Chinese traditional medicine for treating breast disease and preparing technique | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN103893722A (en) | Traditional Chinese medicinal composition for treating solar dermatitis and preparation method thereof | |
| CN103505535B (en) | Medicine used for treating psoriasis as well as extraction method, extract and application thereof | |
| CN101933973B (en) | Pharmaceutical composition for preventing and treating liver injury | |
| CN102626478A (en) | Externally used Chinese herbal medicine compound for treating lumbar muscle strain for years | |
| CN101023982A (en) | Medicine composition for treating osteoporosis | |
| CN102228544B (en) | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof | |
| CN111375038B (en) | Traditional Chinese medicine bath composition for treating psoriasis as well as preparation method and application thereof | |
| CN107569528A (en) | A kind of pharmaceutical composition for treating hepatitis, pharmaceutical preparation and application and preparation method | |
| CN101757104B (en) | Medicament for treating psoriasis | |
| CN114306442A (en) | Traditional Chinese medicine composition for treating atopic dermatitis and application thereof | |
| CN114344423A (en) | Traditional Chinese medicine composition for treating atopic dermatitis and application thereof | |
| CN102698214A (en) | Traditional Chinese medicine for treating migraine and preparation method thereof | |
| CN102343031A (en) | Chinese medicinal composition for treating osteomyelitis | |
| CN110721229A (en) | Formula essential oil for treating hyperplasia of mammary glands | |
| CN103520475B (en) | A kind of pharmaceutical composition being used for the treatment of skin pruritus | |
| CN104740557A (en) | Traditional Chinese medicine composition and cream for treating rheumatism and preparation method of traditional Chinese medicine composition and cream | |
| CN104274555B (en) | Traditional Chinese medicine composition for treating rheumatism, ointment and preparation method of traditional Chinese medicine composition | |
| CN109331100A (en) | It is a kind of for treating the Chinese medicine composition of cerebral infarction sequelae | |
| CN117064974B (en) | Traditional Chinese medicine composition and traditional Chinese medicine plaster for detumescence and analgesia of knee osteoarthritis and preparation method of traditional Chinese medicine plaster | |
| Xiao et al. | Immunostimulants in traditional Chinese medicine | |
| CN102309620A (en) | Chinese medicinal preparation for treating constipation and preparation method thereof | |
| CN105362562A (en) | Pharmaceutical composition for treating herpes zoster | |
| CN115068561A (en) | Traditional Chinese medicine composition for treating atopic dermatitis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221020 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150506 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |